Landon N Olp1, Veenu Minhas1, Clement Gondwe1, Chipepo Kankasa1, Janet Wojcicki1, Charles Mitchell1, John T West1, Charles Wood2. 1. Nebraska Center for Virology and School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE (LNO, VM, JTW); Department of Pediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia (CG, CK); Department of Pediatrics and Department of Nutrition, University of California, San Francisco, CA (JW); Department of Pediatric Immunology/Infectious Diseases, University of Miami School of Medicine, Miami, FL (CM); Nebraska Center for Virology and School of Biological Sciences (CW) and Department of Biochemistry (CW), University of Nebraska-Lincoln, Lincoln, NE. Current affiliation: Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha NE (VM). 2. Nebraska Center for Virology and School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE (LNO, VM, JTW); Department of Pediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia (CG, CK); Department of Pediatrics and Department of Nutrition, University of California, San Francisco, CA (JW); Department of Pediatric Immunology/Infectious Diseases, University of Miami School of Medicine, Miami, FL (CM); Nebraska Center for Virology and School of Biological Sciences (CW) and Department of Biochemistry (CW), University of Nebraska-Lincoln, Lincoln, NE. Current affiliation: Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha NE (VM). cwood1@unl.edu.
Abstract
BACKGROUND: The risk of Kaposi's sarcoma-associated herpesvirus (KSHV) acquisition among children is increased by HIV infection. Antiretroviral therapy (ART) was recently made widely available to HIV-infected children in Zambia. However, the impact of early ART on KSHV transmission to HIV-infected children is unknown. METHODS: We enrolled and followed a cohort of 287 HIV-exposed, KSHV-negative children under 12 months of age from Lusaka, Zambia, to identify KSHV seroconversion events. Potential factors associated with KSHV infection-with an emphasis on HIV, ART, and immunological measures-were assessed through structured questionnaires and blood analyses. Incidence rate, Kaplan-Meier, and multivariable Cox regression models were used to assess differences in time to event (KSHV seroconversion) between groups. All statistical tests were two-sided. RESULTS: During follow-up, 151 (52.6%) children underwent KSHV seroconversion. Based on 3552 months of follow-up, we observed similar KSHV incidence rates between HIV-infected and uninfected children. Among HIV-infected children, ART-naïve children had statistically significantly increased risk of KSHV acquisition (adjusted hazard ratio [AHR] = 5.04, 95% confidence interval [CI] = 2.36 to 10.80, P < .001). Time-updated CD4(+) T-cell percentage was also statistically significantly associated with risk of KSHV acquisition (AHR = 0.82, 95% CI = 0.74 to 0.92, P < .001), such that each 5% increase of CD4(+) T-cells represented an 18% decrease in risk of acquiring KSHV. CONCLUSIONS: Our data suggest that early ART and prevention of immune suppression reduce the risk of KSHV acquisition among HIV-infected children in an area where both viruses are highly endemic. This study highlights the importance of programs in Africa to provide children with ART immediately after HIV infection is diagnosed.
BACKGROUND: The risk of Kaposi's sarcoma-associated herpesvirus (KSHV) acquisition among children is increased by HIV infection. Antiretroviral therapy (ART) was recently made widely available to HIV-infectedchildren in Zambia. However, the impact of early ART on KSHV transmission to HIV-infectedchildren is unknown. METHODS: We enrolled and followed a cohort of 287 HIV-exposed, KSHV-negative children under 12 months of age from Lusaka, Zambia, to identify KSHV seroconversion events. Potential factors associated with KSHV infection-with an emphasis on HIV, ART, and immunological measures-were assessed through structured questionnaires and blood analyses. Incidence rate, Kaplan-Meier, and multivariable Cox regression models were used to assess differences in time to event (KSHV seroconversion) between groups. All statistical tests were two-sided. RESULTS: During follow-up, 151 (52.6%) children underwent KSHV seroconversion. Based on 3552 months of follow-up, we observed similar KSHV incidence rates between HIV-infected and uninfected children. Among HIV-infectedchildren, ART-naïve children had statistically significantly increased risk of KSHV acquisition (adjusted hazard ratio [AHR] = 5.04, 95% confidence interval [CI] = 2.36 to 10.80, P < .001). Time-updated CD4(+) T-cell percentage was also statistically significantly associated with risk of KSHV acquisition (AHR = 0.82, 95% CI = 0.74 to 0.92, P < .001), such that each 5% increase of CD4(+) T-cells represented an 18% decrease in risk of acquiring KSHV. CONCLUSIONS: Our data suggest that early ART and prevention of immune suppression reduce the risk of KSHV acquisition among HIV-infectedchildren in an area where both viruses are highly endemic. This study highlights the importance of programs in Africa to provide children with ART immediately after HIV infection is diagnosed.
Authors: D Max Parkin; Freddy Sitas; Mike Chirenje; Lara Stein; Raymond Abratt; Henry Wabinga Journal: Lancet Oncol Date: 2008-07 Impact factor: 41.316
Authors: Martin Dedicoat; Robert Newton; Khaled R Alkharsah; Julie Sheldon; Ildiko Szabados; Bukekile Ndlovu; Taryn Page; Delphine Casabonne; Charles F Gilks; Sharon A Cassol; Denise Whitby; Thomas F Schulz Journal: J Infect Dis Date: 2004-08-11 Impact factor: 5.226
Authors: Sam M Mbulaiteye; Ruth M Pfeiffer; Eric A Engels; Vickie Marshall; Paul M Bakaki; Anchilla M Owor; Christopher M Ndugwa; Edward Katongole-Mbidde; James J Goedert; Robert J Biggar; Denise Whitby Journal: J Infect Dis Date: 2004-09-10 Impact factor: 5.226
Authors: Brad P Brayfield; Chipepo Kankasa; John T West; Jubra Muyanga; Ganapati Bhat; Winslow Klaskala; Charles D Mitchell; Charles Wood Journal: J Infect Dis Date: 2004-05-25 Impact factor: 5.226
Authors: Veenu Minhas; Kay L Crabtree; Ann Chao; Tendai J M'soka; Chipepo Kankasa; Marc Bulterys; Charles D Mitchell; Charles Wood Journal: Am J Epidemiol Date: 2008-05-30 Impact factor: 4.897
Authors: Kay L Crabtree; Janet M Wojcicki; Veenu Minhas; Chipepo Kankasa; Charles Mitchell; Charles Wood Journal: J Infect Dis Date: 2017-10-17 Impact factor: 5.226